Drug intelligence / Profile preview

NB1000S

Development stage: Unknown
Lead developer: Novome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NB1000S is a proprietary, genetically engineered microbial strain of *Bacteroides* developed by Novome Biotechnologies. [1-1, 2-3] It is a recombinant live biotherapeutic product designed to degrade oxalate in the gastrointestinal tract to reduce high urinary oxalate levels. [2-3, 2-11] NB1000S is a key component of the investigational combination product NOV-001, where its engraftment in the gut is controllably supported by a co-administered prebiotic polysaccharide, NB2000P. [2-1, 2-3, 5-1] NOV-001 is being developed for the treatment of enteric hyperoxaluria to prevent recurrent kidney stones and progressive kidney failure. [2-11, 2-13]

Beyond the preview

Go deeper on NB1000S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB1000S.

Explore the full profile